Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer

Stopped early · Phase 2

Conditions studied: Prostate Cancer

In brief

The purpose of this study is to assess the change in quality of life over a 6 month period between gabapentin and venlafaxine in men with prostate cancer treated for hot flashes related to androgen deprivation therapy.

Key facts

Study ID

NCT01533753

Run by

University of Wisconsin, Madison

People needed

5

Starts

2012-02-01

Expected to finish

2014-05-01

Last updated by the study team

2019-11-21

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Men 18 years or older with histologically proven adenocarcinoma of the prostate
• Prior or current androgen deprivation for at least 6 months prior to study entry with either bilateral orchiectomy or being maintained on a stable dose of LHRH (luteinizing hormone-releasing hormone) agonist or antagonist
• Hot flash frequency of an average of 2 or more per day (average of 14 hot flash episodes per week)

You may not qualify if…

• cannot currently be taking serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs) or monoamine oxidase inhibitors (MAOIs)
• cannot have uncontrolled hypertension
• cannot have history of past or current of epilepsy, epilepsy syndrome or other seizure disorder
• cannot have psychiatric history of mania, hypomania, bipolar disorder or anorexia nervosa
• cannot be receiving concurrent treatment with amy medications or herbal products being used with the express purpose of treating hot flashes.

Where it is running

• University of Wisconsin Hospital and Clinics (Carbone Cancer Center) — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.